House Dust Mite Allergy - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

House Dust Mite Allergy - Pipeline Review, H2 2016

House Dust Mite Allergy - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
House Dust Mite Allergy - Pipeline Review, H2 2016
Published Jul 20, 2016
53 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, House Dust Mite Allergy - Pipeline Review, H2 2016, provides an overview of the House Dust Mite Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for House Dust Mite Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for House Dust Mite Allergy and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy
- The report reviews pipeline therapeutics for House Dust Mite Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved House Dust Mite Allergy therapeutics and enlists all their major and minor projects
- The report assesses House Dust Mite Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for House Dust Mite Allergy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for House Dust Mite Allergy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding

  
Source:
Document ID
GMDHC8254IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
House Dust Mite Allergy Overview61
Therapeutics Development71
  Pipeline Products for House Dust Mite Allergy Overview71
House Dust Mite Allergy Therapeutics under Development by Companies81
House Dust Mite Allergy Pipeline Products Glance93
  Late Stage Products91
  Clinical Stage Products101
  Early Stage Products111
House Dust Mite Allergy Products under Development by Companies121
House Dust Mite Allergy Companies Involved in Therapeutics Development136
  ALK-Abello A/S131
  Anergis SA141
  Biomay AG151
  Circassia Pharmaceuticals Plc161
  HAL Allergy BV171
  Stallergenes SAS181
House Dust Mite Allergy Therapeutics Assessment197
  Assessment by Monotherapy Products191
  Assessment by Combination Products201
  Assessment by Target211
  Assessment by Route of Administration222
  Assessment by Molecule Type242
Drug Profiles2613
  AllerDM Drug Profile261
  Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis Drug Profile271
  BM-35 Drug Profile281
  PL-103 Drug Profile291
  standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract Drug Profile302
  standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine Drug Profile325
  Vaccine for House Dust Mite Induced Allergic Rhinoconjunctivitis Drug Profile372
House Dust Mite Allergy Dormant Projects391
House Dust Mite Allergy Discontinued Products401
House Dust Mite Allergy Product Development Milestones4111
  Featured News &Press Releases411
    Apr 27, 2016: Journal of the American Medical Association publishes Phase III data from allergic asthma trial with ALK house dust mite SLIT-tablet, ACARIZAX411
    Apr 13, 2016: License application for investigational house dust mite SLIT-tablet accepted for review by FDA421
    Apr 12, 2016: Merck Announces FDA Acceptance of Biologics License Application for Investigational House Dust Mite Sublingual Allergy Immunotherapy Tablet421
    Jan 27, 2016: Marketing authorisation for ACARIZAX issued in France421
    Dec 09, 2015: New product (ACARIZAX) for treatment of house dust mite allergic rhinitis and asthma obtains reimbursement in Denmark431
    Nov 26, 2015: New medicine for house dust mite allergic rhinitis now available in Japan441
    Nov 19, 2015: Desensitization Therapy Actair House Dust Mite Sublingual Tablets Launched in Japan441
    Jun 09, 2015: ALK s partner, MSD, publishes Phase II data on house dust mite SLIT-tablet in leading allergy journal451
    Jun 04, 2015: ALK announces top-line results from its partner MSD's North American Phase III trial of house dust mite SLIT-tablet461
    Jun 16, 2014: ALK's Partner for Japan Announces Trial Results for House Dust Mite SLIT-Tablet461
    Jun 13, 2014: Circassia Announces Results from House Dust Mite Allergy Treatment Phase IIb Two-Year Follow-up Study471
    Mar 20, 2014: ALK's Partner Merck Initiates Phase III Clinical Development Programme in North America with the New Allergy Immunotherapy Tablet481
    Mar 20, 2014: House dust mite SLIT-tablet enters Phase III clinical development491
    Mar 04, 2014: Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet501
    Sep 12, 2013: Circassia's house dust mite allergy treatment achieves long-term symptom reduction511
Appendix522
  Methodology521
  Coverage521
  Secondary Research521
  Primary Research521
  Expert Panel Validation521
  Contact Us521
  Disclaimer531

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "House Dust Mite Allergy - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/House-Dust-Mite-Allergy-Pipeline-Review-H2-2016-2088-16228>
  
APA:
Global Markets Direct - Market Research. (2016). House Dust Mite Allergy - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/House-Dust-Mite-Allergy-Pipeline-Review-H2-2016-2088-16228>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.